Oral Presentations 2 by unknown
ORAL PRESENTATIONS 2
2.1
BUB1 AND AURORA COOPERATE TO MAINTAIN 
CHROMOSOME STABILITY
S Taylor 
United Kingdom, Manchester University, Manchester
The majority of human cancer cells  are aneuploid due to an underlying 
chromosome instability phenotype. This observation raises three questions: 
(1) what are the basic mechanisms which normally operate to maintain 
chromosome stability? (2) what aspects of these mechanisms go wrong during 
tumour evolution? and (3) can these defects be exploited to develop novel anti-
cancer strategies? In order to address these questions, our research focuses on 
the spindle checkpoint.
The spindle checkpoint maintains chromosome stability by inhibiting the 
anaphase promoting complex (APC) until all the chromosomes correctly 
align on the microtubule spindle via their kinetochores. BubR1, an essential 
component of this checkpoint, localises to kinetochores and its kinase 
activity is regulated by the kinesin related motor protein Cenp-E. BubR1 also 
inhibits APC in vitro, thus providing a molecular link between kinetochore 
– microtubule interactions and the proteolytic machinery that regulates mitotic 
progression. 
Several other protein kinases, including Bub1 and members of the Ipl1/Aurora 
family, also regulate anaphase onset. However, in human somatic cells Bub1 
and Aurora kinase activity do not appear to be essential for checkpoint 
function: when Bub1 is repressed by RNAi or Aurora kinase activity inhibited 
with the small molecule ZM447439, cells arrest in mitosis when the spindle is 
destroyed. However, we have recently discovered that when Bub1 and Aurora 
are simultaneously inhibited, the checkpoint is compromised. 
One explanation for this is that the checkpoint is composed of two arms, 
one dependent on Bub1, the other on Aurora. We suggest that both arms 
converge on BubR1, promoting its ability to bind APC and that these two arms 
respond to different spindle cues: while the Bub1 arm monitors microtubule 
attachment, the Aurora arm monitors biorientation. This bifurcation in the 
signaling mechanism may help explain why many tumor cells mount a 
robust checkpoint response following spindle damage despite exhibiting 
chromosome instability. In addition, it opens up the opportunity of developing 
novel “synthetic lethality” based anti-cancer strategies.
2.2
SYNERGISTIC INHIBITION OF TUMOUR CELL 
PROLIFERATION AND UPREGULATION OF HIF-1α USING TWO 
ANTI-TRANSFERRIN RECEPTOR ANTIBODIES.
D.T. Jones 1, H Turley 1, P Ratcliffe 2, A.L. Harris 1
1 Cancer Research UK, Weatherall Institute of Molecular Medicine, 
Oxford, United Kingdom, 2 The Wellcome Trust Centre for Human 
Genetics, Oxford, United Kingdom
Iron is needed for hydroxylation of hypoxia inducible factor-1α (Hif-1α) by
prolyl hydroxylases.  Uptake of iron by cells is mediated by a cell surface
transferrin receptor (TfR), and some tumour cells express higher levels TfR
compared to normal cells. In previous studies, combinations of monoclonal
antibodies (MAbs) against TfR of human tumour cells have shown
antiproliferative effects. Two MAbs E2.3 and A27.15 against TfR were tested
for their ability to inhibit growth of breast cancer cell line MDA-MB-468 and
to induce Hif-1α and hypoxia regulated genes in-vitro. 
Inhibition of cell proliferation was not observed after 4 days with up
to 250µg/ml E2.3, while 250µg/ml A27.15 inhibited 17% cell growth.
However, equal combination of E2.3 and A27.15 as low as 10µg/ml inhibited
cell proliferation, with 56% inhibition of cell growth when combined MAbs
were used at 250µg/ml. Synergistic upregulation of angiogenic factor VEGF
was also observed when anti-TfR MAbs were combined. VEGF increased
by 336% with combined 5 µg/ml MAbs after 4days, while E2.3 and A27.15
alone only increased VEGF by 19% and 35% respectively at 5µg/ml.
Synergistic effect of anti-TfR MAbs was further validated by western
blotting with MAbs against Hif-1α, and carbonic anhydrase IX (CAIX) a
Hif-1α regulated gene.  CAIX and Hif-1α were moderately upregulated by
50µg/ml of A27.15 and E2.3 when used alone, while combined anti-TfR
MAbs synergistically upregulated CAIX and Hif-1α. Combined anti-TfR
MAbs also downregulated the expression of TfR, while no change was
observed when anti-TfR MAbs were used individually. 
Treatment of breast cancer cell line with combined MAbs clearly inhibited
cell growth and activated Hif-1α and Hif-1α regulated genes VEGF
and CAIX synergistically. Combined anti-TfR MAbs could be used in
combination with anti-Hif modulators to further inhibit cell growth in-vitro.
2.3
ROLE OF HIF TARGET GENES BNIP3 AND CARBONIC 
ANHYDRASE 9 (CA9) IN HYPOXIA INDUCED CELL DEATH
AL Bacon , N Robertson , M Kouokourakis , AL Harris 
Cancer Research UK, Wetherall Institute of Molecular Medicine, 
Oxford, United Kingdom
Hypoxia, via HIF1, upregulates many genes involved in cell survival 
and angiogenesis. However pro-apoptotic pathways are also induced 
and those involved in pH regulation. We have investigated 2 such 
pathways that are up-regulated in most cancers, by RNA interference 
(RNAi) for their role in survival under hypoxia.
BNIP3 is a pro-apoptotic protein that is hypoxically up-regulated in 
cancer cell lines and tissues. We show that inactivation of HIF1A in 
MDA-435 by RNAi prevents the hypoxic up-regulation of BNIP3. 
While hypoxia causes reduced cell growth and increased cell death 
compared to normoxia, inactivation of BNIP3 reduces hypoxic induced 
cell death. We are exploring whether BNIP3 acts via a necrotic or 
apoptotic pathway and also investigating mechanisms by which cancer 
cells may overcome such cell death signals. 
CA9 is a member of the α class of carbonic anhydrases (CAs) that 
catalyse the reversible hydration of CO2 (H2O + CO2 ⇔ H+ + HCO3
-). 
It is over-expressed in a variety of tumour types and associated with 
increased metastasis and poor prognosis. RNAi was used to examine 
the cellular function of CA9 in MDA-468 breast carcinoma. Protein 
expression was signiﬁ  cantly reduced in a dose-dependent manner, and 
this resulted in a 3-4 day growth delay in monolayer culture, and a 50% 
reduction in clonogenic survival under both normoxic and hypoxic 
conditions. This reduction in survival appears to be related to the role 
of CA9 in intracellular pH homeostasis, and makes CA9 an attractive 
target for cancer therapy.
Clinical application of these ﬁ  ndings shows that in a series of 105 
non small cell lung cancers treated by surgery alone, high BNIP3 was 
associated with poor survival and a subset had nuclear localisation of 
BNIP3, providing 1 mechanism for bypass of this pathway. These results 
suggest high levels of BNIP3 help select for an aggressive phenotype to 
bypass the pathway thus allowing for clonal selection.
2.4
MMP-7 ACTS AS A SIGNAL FROM EPITHELIAL CELLS TO 
MYOFIBROBLASTS IN GASTRIC CARCINOID TUMOURS
A Varro 1, E Hemers 1, DM Pritchard 2
1 Dept Physiology, Univ Liverpool, Liverpool, United Kingdom, 2 Dept 
Medicine, Univ Liverpool, Liverpool, United Kingdom
Background & Aims: Prolonged elevation of the gastric hormone gastrin
is virtually always associated with hyperplasia of enterochromafﬁ  n-like
(ECL) cells and in some patients this progresses to gastric carcinoid
tumours. The latter consist of both epithelial tissue and stroma, and
both compartments may regress after removal of the gastrin-producing
part of the stomach. Gastrin only acts on epithelial cells, so that these
tumours provide a model for the identiﬁ  cation of signalling pathways
from epithelium to sub-epithelial cells. We previously identiﬁ  ed
increased MMP-7 expression in pre-neoplastic gastric epithelial cells;
we have now examined whether MMP-7 acts as a signal from epithelial
to myoﬁ  broblast cells. 
Procedures: Gastric biopsies were obtained from patients with elevated
plasma gastrin due to pernicious anaemia (PA) or gastrinoma on
background of multiple endocrine neoplasia type 1 (MEN-1). MMP-
7 was detected by Western blotting and immunohistochemistry;
expression was studied using a promoter-reporter (luciferase) construct.
Cultured myoﬁ  broblast responses to recombinant MMP-7 were studied
by [3H] thymidine incorporation and Western blotting of phophorylated
signalling molecules.
Results: There was increased MMP-7 abundance in gastric biopsies of
patients with PA and MEN-1, including ECL cell carcinoid tumours.
In the latter, MMP-7 was localised to ECL cells but not stromal cells
which were nevertheless well represented. An MMP-7 luciferase
promoter reporter indicated that gastrin stimulated MMP-7 expression
both directly and via COX-2. rMMP-7 stimulated the proliferation
of myoﬁ   broblasts and this response was reversed by inhibitors of
MEK (UO126) and PI3K (LY294002). Moreover rMMP-7 increased
phosphorylation of p42/44 ERK and of Akt.  Conclusion:  MMP-7
may act as an epithelial-mesenchymal signal regulating myoﬁ  broblast
function by activation of the MAPkinase and PI3kinase pathways.
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ROLE OF KERATINOCYTE GROWTH FACTOR (KGF) AND 
ANDROGEN IN HUMAN PROSTATIC EPITHELIAL STEM CELL 
DIFFERENTIATION
R Heer , AT Collins , CN Robson , HY Leung 
Urology Research Group, Northern institute for cancer research, 
Newcastle upon Tyne, United Kingdom
Introduction:  Understanding stem cell regulation may provide 
useful insight into the pathogenesis prostate cancer. It is thought that 
integrins play an important role in maintaining cells within stem cell 
compartment.  We investigated the effect of blocking of the beta1 
integrin function on prostate epithelial stem cells in addition to KGF 
and androgen, which are essential in prostate development. 
Methods: Benign tissue from resected prostate samples was used to 
select stem cells (Collins et al., J Cell Sci 2001; 114:3865-72) which 
were either incubated with a blocking anti-beta1 integrin antibody, or 
treated with KGF (10ng/ml) or androgen analogue R1881 (10nM). 
Differentiation was characterised by expression of prostate acid 
phosphatase (PAP), androgen receptor (AR) and cytokeratin18 (CK18) 
using FACS analysis. Expression of alpha2 beta1 integrin was also 
examined.
Results: Blocking beta1 integrin resulted in up-regulation of PAP and 
CK18 (60% and 3% respecitvely, p<0.001) and no increase in AR 
levels. Treatment with KGF resulted in the down regulation of alpha2 
beta1 integrin (61% decrease, p <0.001) and increases in PAP, CK18 
and AR (35%, 36% and 39% increases respectively, p<0.001). R1881 
treatment also resulted in the down regulation of alpha2 beta1 integrin 
(60% decrease, p <0.001) with concurrent increases in PAP, CK18, AR 
(33%, 36% and 34% respectively, p<0.001). These effects of KGF and 
R1881 markers of differentiation were speciﬁ  cally inhibited using SB 
202190 (5uM) and casodex (10uM) (p<0.05).
Conclusions:  Speciﬁ   cally blocking the beta1 integrin, induces exit 
from the prostate epithelial stem cell compartment as determined by the 
expression of PAP and CK18.  KGF and androgen act to down regulate 
alpha2 beta1 integrin causing differentiation with the additional effect 
of inducing AR expression.
2.6
GASTRIN INDUCED ACTIVATION OF PKB/AKT IN BARRETT’S 
OESOPHAGUS
JC Harris 1, PA Clarke 1, A Awan 1, J Jankowski 2, SA Watson 1
1 Cancer Studies Unit, University of Nottingham, Nottingham, United 
Kingdom, 2 Department of Cancer Biomarkers, University of Leicester,
Leicester, United Kingdom
Gastrin and isoforms of the gastrin/CCK-2 receptor (including the
constitutively active CCK-2Ri4sv) have previously been shown to act in an
oncogenic fashion in the gastrointestinal tract, whilst activation of PKB/
Akt is increasingly being seen as a key prognostic and controlling factor
in carcinogenesis. This study aimed to determine a link between gastrin
expression, PKB/Akt activation and subsequent IκBα degradation in the
oesophageal environment, particularly in the development and progression
of Barrett’s oesophagus (BE). 
Expression of gastrin (n=16) and CCK-2R (n=18) in normal and BE
biopsy samples was quantiﬁ  ed via real-time PCR, with immuno-staining
used to conﬁ  rm PKB/Akt expression (n=8). Effects of exogenous and
endogenous gastrin on PKB/Akt phosphorylation and IκBα degradation
in two CCK-2R positive oesophageal cell lines (OE19 and OE33) was
assessed via Western blotting with in vitro IC50 cytotoxicity assays used to
assess cisplatin sensitivity.
In vitro studies demonstrated that exogenous and endogenous gastrin can
stimulate PKB/Akt activation and IκBα degradation in oesophageal cell
lines. CCK-2R blockade causes a reversal of this phenomenon. Gastrin
or CCK-2Ri4sv mediated PKB/Akt activation was shown to confer cells
with increased cisplatin resistance. Human BE biopsy samples showed
a signiﬁ   cant increase in gastrin (p=0.0076) and CCK-2R (p=0.0068)
expression as well as PKB/Akt activation compared to normal tissue
(p<0.008). 
The CCK-2Ri4sv and gastrin autocrine and endocrine pathways can
activate PKB/Akt as well as downstream targets in vitro, a mechanism
potentially leading to increased resistance to cisplatin. It is suggested that
the observed increase in PKB/Akt activation seen in human BE compared
to normal samples could result from a similar process. We hence propose
PKB/Akt as a potential prognostic marker and chemotherapeutic target in
BE and oesophageal adenocarcinoma.
2.7
LRP IS DIFFERENTIALLY EXPRESSED IN HUMAN 
GLIOBLASTOMA CELL LINES AND ITS LOW EXPRESSION 
IS ASSOCIATED WITH INCREASE IN ASTROCYTIC TUMOR 
GRADE
R Abdel-Fattah , I.M Hussaini 
University of Virginia, Charlottesville, United States
Low-density lipoprotein receptor-related protein (LRP) is expressed in 
numerous cell-types and plays an important role in regulating proteinase 
activity. The receptor binds a repertoire of ligands, which have diverse 
biologic functions.  The amount of LRP expressed on the cell surface 
varies between tissue types. In this study, we investigated whether LRP 
is differentially expressed among normal astrocytes, astrocytic tumors 
and different glioma cell lines (U-1242 MG, U-251 MG, U-373 MG 
and U-87 MG) using Western, Northern blot analyses and RT-PCR. 
We also determined LRP immunoreactivity in pilocytic astrocytoma, 
diffuse-type astrocytomas grade II/III and GBM (grade IV) using 
immunohistochemistry (IHC). A speciﬁ   c monoclonal antibody (11H4) 
was used against the transmembrane domain of the LRP to detect the 
85-kDa band using Western blot analysis. All cell lines exhibited LRP, 
but expression was variable. The primary astrocytes expressed the 
highest level of the receptor protein followed by U-87 MG, U-1242 MG, 
U-251 MG and then U-373 MG cells. Expression of LRP in astrocytic 
cells was also conﬁ  rmed by Northern blot analysis.  As expected, the 
primary astrocytes expressed the highest level of the LRP mRNA (15 
kb), suggesting that LRP expression is regulated differently in these cell 
lines. LRP expression using RT-PCR was in complete agreement with the 
Western and Northern blot analyses. Using IHC, the pilocytic astrocytoma 
expressed higher LRP-immunoreactivity than in astrocytoma II and III 
specimens or the GBM sample. We also performed Western blot analysis 
on frozen astrocytoma specimens and compared those with non-neoplastic 
astrocytes (NHA).  LRP protein expression was higher in NHA and the two 
pilocytic astrocytomas compared to the GBM specimens. In conclusion, 
LRP expression decreases with increase in astrocytic tumor grade. Thus, 
LRP could potentially be a promising new approach for the management 
of malignant gliomas.
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